Cargando…

Cost utility analysis of Remdesivir and Dexamethasone treatment for hospitalised COVID-19 patients - a hypothetical study

BACKGROUND: Sars-Cov-2 is a novel corona virus associated with significant morbidity and mortality. Remdesivir and Dexamethasone are two treatments that have shown to be effective against the Sars-Cov-2 associated disease. However, a cost-effectiveness analysis of the two treatments is still lacking...

Descripción completa

Detalles Bibliográficos
Autores principales:	Carta, Andrea, Conversano, Claudio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8449700/ https://www.ncbi.nlm.nih.gov/pubmed/34537034 http://dx.doi.org/10.1186/s12913-021-06998-w

Ejemplares similares

Baricitinib + remdesivir cost saving vs remdesivir for hospitalised COVID-19 patients in the USA
Publicado: (2021)

Cost-effectiveness of Remdesivir and Dexamethasone for COVID-19 Treatment in South Africa
por: Jo, Youngji, et al.
Publicado: (2021)

Fewer COVID‐19 Neurological Complications with Dexamethasone and Remdesivir
por: Grundmann, Alexander, et al.
Publicado: (2022)

Modeling the Potential Impact of Remdesivir Treatment for Hospitalized Patients with COVID-19 in Saudi Arabia on Healthcare Resource Use and Direct Hospital Costs: A Hypothetical Study
por: Ruggeri, Matteo, et al.
Publicado: (2022)

Estimation Model for Healthcare Costs and Intensive Care Units Access for Covid-19 Patients and Evaluation of the Effects of Remdesivir in the Portuguese Context: Hypothetical Study
por: Ruggeri, Matteo, et al.
Publicado: (2022)

REMDESIVIR-ASSOCIATED ASYMPTOMATIC BRADYCARDIA IN AN ICU PATIENT ON DEXAMETHASONE FOR COVID-19
por: HAIDER, MOBEEN, et al.
Publicado: (2022)

Dexamethasone in hospitalised patients with COVID-19: addressing uncertainties
por: Matthay, Michael A, et al.
Publicado: (2020)

Efficacy and safety of remdesivir in hospitalised COVID-19 patients: a systematic review and meta-analysis
por: Angamo, Mulugeta T., et al.
Publicado: (2021)

A Retrospective Study of Dexamethasone, Remdesivir, and Baricitinib in Severe COVID-19
por: Ngo, Dallis Q., et al.
Publicado: (2022)

Dexamethasone in hospitalised COVID-19 patients not on intensive respiratory support
por: Crothers, Kristina, et al.
Publicado: (2022)

A case report of COVID-19 in refractory myasthenia: Outcome with remdesivir and dexamethasone
por: Bhagavan, Sachin M., et al.
Publicado: (2021)

THE EFFICACY OF REMDESIVIR WITH DEXAMETHASONE VS. DEXAMETHASONE ALONE IN ADULTS HOSPITALIZED WITH COVID-19: A RETROSPECTIVE COHORT STUDY
por: AL-MISTAREHI, ABDEL-HAMEED, et al.
Publicado: (2022)

Clinical impact of combination therapy with baricitinib, remdesivir, and dexamethasone in patients with severe COVID-19
por: Izumo, Takehiro, et al.
Publicado: (2021)

Remdesivir in combination with dexamethasone for patients hospitalized with COVID-19: A retrospective multicenter study
por: Gressens, Simon B., et al.
Publicado: (2022)

The Cost-Effectiveness of Remdesivir for Hospitalized Patients With COVID-19
por: Whittington, Melanie D., et al.
Publicado: (2022)

Dexamethasone/remdesivir: Acute pancreatitis: case report
Publicado: (2022)

Safety and clinical outcomes of remdesivir in hospitalised COVID-19 patients: a retrospective analysis of active surveillance database
por: Gupte, Vaishali, et al.
Publicado: (2022)

Prognostic factors of 30-day mortality in patients with COVID-19 pneumonia under standard remdesivir and dexamethasone treatment
por: Choi, Yu Jung, et al.
Publicado: (2022)

Cost-Effectiveness of Remdesivir for COVID-19 Treatment: What Are We Missing?
por: Chhatwal, Jagpreet, et al.
Publicado: (2022)

Dexamethasone/remdesivir: Sinus bradycardia and off label use in COVID-19 and :case report
Publicado: (2021)

Dexamethasone mitigates remdesivir-induced liver toxicity in human primary hepatocytes and COVID-19 patients
por: Liu, Kaiyan, et al.
Publicado: (2023)

A Cost-Effectiveness Analysis of Remdesivir for the Treatment of Hospitalized Patients With COVID-19 in England and Wales
por: Rafia, Rachid, et al.
Publicado: (2022)

Remdesivir cost effective for severe COVID-19 in China
Publicado: (2021)

Length of remdesivir treatment in patients with severe COVID-19
por: Ippolito, Mariachiara, et al.
Publicado: (2021)

Cost–Utility Analysis of Pharmacogenetic Testing Based on CYP2C19 or CYP2D6 in Major Depressive Disorder: Assessing the Drivers of Different Cost-Effectiveness Levels from an Italian Societal Perspective
por: Carta, Andrea, et al.
Publicado: (2022)

Dexamethasone/propofol/remdesivir: Various toxicities: case report
Publicado: (2021)

Antibacterials/dexamethasone/remdesivir: Lack of efficacy: case report
Publicado: (2022)

Dexamethasone/remdesivir/tocilizumab: Various toxicities: case report
Publicado: (2022)

Dexamethasone/remdesivir/tocilizumab: Lack of efficacy: case report
Publicado: (2022)

On the Use of Markov Models in Pharmacoeconomics: Pros and Cons and Implications for Policy Makers
por: Carta, Andrea, et al.
Publicado: (2020)

Tocilizumab, Remdesivir, Favipiravir, and Dexamethasone Repurposed for COVID-19: a Comprehensive Clinical and Pharmacovigilant Reassessment
por: Kelleni, Mina T.
Publicado: (2021)

Efficacy of the combination of baricitinib, remdesivir, and dexamethasone in hypoxic adults with COVID-19: A retrospective study
por: Yasuda, Yuto, et al.
Publicado: (2022)

POSC41 Cost-Effectiveness Analysis of Remdesivir for the Treatment of COVID-19 Hospitalized Adults in Mexico
por: Ponce-de-León, A, et al.
Publicado: (2022)

EE527 Cost-Effectiveness and Budget Impact Analysis of Remdesivir for the Treatment of COVID-19 in Greece
por: Athanasakis, K, et al.
Publicado: (2022)

Cost-effectiveness of remdesivir for the treatment of hospitalized patients with COVID-19: a systematic review
por: Rezapour, Aziz, et al.
Publicado: (2023)

Rapid Response to Remdesivir in Hospitalised COVID-19 Patients: A Propensity Score Weighted Multicentre Cohort Study
por: Leegwater, Emiel, et al.
Publicado: (2023)

Viable SARS-CoV-2 shedding under remdesivir and dexamethasone treatment
por: Yoon, Jin Gu, et al.
Publicado: (2022)

Efficacy and Outcome of Remdesivir and Tocilizumab Combination Against Dexamethasone for the Treatment of Severe COVID-19: A Randomized Controlled Trial
por: Mohiuddin Chowdhury, Abu Taiub Mohammed, et al.
Publicado: (2022)

Phase 2 randomised placebo-controlled trial of spironolactone and dexamethasone versus dexamethasone in COVID-19 hospitalised patients in Delhi
por: Wadhwa, Bharti, et al.
Publicado: (2023)

The place for remdesivir in COVID-19 treatment
por: Young, Barnaby, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_j8cksbv0hn1jice93ge44jeh1v